股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定/註冊股本總額： HKD 5,000,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年1月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 FF301 公司名稱: ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定/ ...

Core Viewpoint - TATA Health (01255.HK) resumed trading on December 1 after a 1.5-year suspension, experiencing a significant initial surge of 566.67% to close at HKD 2.00 per share, but subsequently faced a decline, closing at HKD 1.60 on December 12, a drop of 37.50% [1]. Group 1: Company Background - TATA Health, originally known as Hong Kong Retail International Holdings Limited, was listed on the Hong Kong Stock Exchange in 2013, initially focusing on shoe sales, representing brands like Clarks and Josef Seibel, but later shifted its focus to the health sector and financial services [3][5]. - The company has struggled to achieve profitability since its listing, with only three profitable years from 2013 to 2024, accumulating a total net profit of HKD 33.58 million over 12 years, while suffering significant losses, particularly a loss of HKD 152 million in 2020 [6][11]. Group 2: Business Operations - TATA Health's shoe business was primarily focused on the Hong Kong market, relying heavily on tourism, which has been impacted by various factors including political unrest and the COVID-19 pandemic, leading to a 20.1% revenue decline in 2019 compared to 2018 [7][8]. - The company attempted to diversify into the health sector, launching a health app in December 2020 and investing in health-related partnerships, but faced challenges due to a lack of experience and competition in the market [10][11]. Group 3: Financial Performance - TATA Health's financial performance has been poor, with the shoe business generating HKD 124.46 million in revenue but incurring a segment loss of HKD 39.93 million [12]. - The company faced severe operational challenges, leading to a suspension of trading in April 2024 due to the inability to publish its 2023 annual results, with potential delisting risks if it failed to meet the resumption conditions within 18 months [11][13].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | ...

Group 1 - TATA Health (1255.HK) resumed trading after more than 1.5 years and saw a significant increase, with midday gains reaching 723.33%, trading at HKD 2.47 [1] - The company is primarily engaged in shoe retail in Hong Kong and has met all resumption guidelines, including publishing outstanding financial results and demonstrating business viability [1] - The trading volume exceeded HKD 17 million, indicating strong market interest following the resumption [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500%, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions [1] - TATA Health confirmed that its business operations are sustainable and that it possesses sufficient operational capacity and valuable assets to support its business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

消息面上，TATA健康发布公告称，公司已达成所有复牌指引，主要包括︰刊发所有未刊发财务业绩及 处理任何审核修订；集团业务持续可行，且有足够的业务运作及相当价值的资产以支持业务营运；及进 行独立内部控制审查，并证明公司已建立充分的内部控制及程序，以履行其于上市规则项下的责任。 TATA健康(01255)时隔逾1年半复牌，早盘飙升超500%，截至发稿，涨520%，报1.86港元，成交额 633.12万港元。 ...

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions, ensuring compliance with regulatory requirements [1] - **Business Viability** - TATA Health confirmed that its business operations are sustainable, with sufficient operational capacity and valuable assets to support ongoing business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

Group 1 - TATA Health (01255.HK) announced that its shares will resume trading at 9:00 AM on December 1, 2025 [1]

Core Viewpoint - TATA Health (01255) has met all resumption guidelines and has applied to the Stock Exchange for the resumption of trading of its shares starting from December 1, 2025, at 9:00 AM [1] Summary by Relevant Sections - Company Status - TATA Health has achieved compliance with all necessary resumption guidelines [1] - The company has submitted an application to the Stock Exchange for the resumption of trading [1] - Trading Resumption - Shares of TATA Health are set to resume trading on December 1, 2025, at 9:00 AM [1]